Group items tagged

A further 18 new products have been entered the list of 'Drugs for which Discount is Not Deducted' (DND) in Part II of the Drug Tariff on 1 November, following applications made by the PSNC. This takes the number of products added to the DND list by the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA) in the last 18 months to over 400. The latest list of products include Aciclovir 200mg/5ml oral suspension sugar free, Acitretin 25mg capsules and Strattera 4mg/1ml oral solution. The DND list is updated monthly by the DHSC and includes grouped and individual items, the latter being separately listed in Part II of the Drug Tariff. Any items covered by the 'Group Items' heading are not listed again individually in Part II. See here to see a list of all the monthly changes to the DND status of products.

The regulators have added 10 new products to the 'Drugs for which Discount is Not Deducted' (DND) list from Thursday (01 June). Community Pharmacy England on behalf of its members had made further applications to the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA), resulting in the inclusion of 10 new products in the DND. More than 610 products are granted DND status following checks made by Community Pharmacy England's dispensing & supply team over the past 3 years to ensure fair reimbursement for our members. The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff. Any items covered by the 'Group Items' heading are not listed again individually in Part II. "We will continue our work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the 'Group' and 'Individual item' criteria and make applications to NHSBSA and DHSC, on behalf of our members accordingly," said Community Pharmacy England.

Nine more new products have been classed as 'Drugs for which Discount is Not Deducted' (DND) from 1 July 2022, announced Department of Health and Social Care (DHSC). This takes the total number of products granted DND status over the past 2 years to over 500 following checks made by the Pharmaceutical Services Negotiating Committee. The Committee had made an application to DHSC and NHSBSA for the following 9 products to be added to the DND list of Individual items to which the discount deduction scale will no longer apply from July 2022: Fludrocortisone 50micrograms/5ml oral suspension (Group) Lorazepam 1mg/5ml oral suspension (Group) Lorazepam 500micrograms/5ml oral suspension (Group) Zopiclone 3.75mg/5ml oral solution (Group) Zopiclone 7.5mg/5ml oral solution (Group) GA explore5 oral powder 12.5g sachets HCU explore5 oral powder 12.5g sachets MSUD explore5 oral powder 12.5g sachets TYR explore5 oral powder 12.5g sachets The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff.

The NHS has made major improvements across long waits, urgent and emergency services, and cancer care, latest performance figures published on Thursday (11) have shown. The number of patients waiting more than 18 months fell to 10,737 by April - down by more than 90 per cent from 124,911 in September 2021 and by more than four-fifths since the start of January when there were 54,882. Around half of NHS trusts in England have no patients on their elective care waiting lists apart from those who have chosen to wait longer. More than one in five (21%) trusts had completely eliminated 18-month waits. However, the overall waiting list has risen to over 7.3 million entries in England. "I promised I would cut NHS waiting lists and we are delivering," Prime Minister Rishi Sunak said. "Reducing 18-month waits by over 90 per cent is huge progress, and it is testament to the hard work of NHS staff who have achieved this despite one of the busiest winters on record. "We still have work to do, but backed by record government investment and the ongoing efforts of the NHS, I am confident we will get patients the care they need more quickly." Ambulance response rates have improved to their fastest in two years, with average category two response times now at 28.5 minutes and category one at 8 mins. The 62-day cancer backlog has fallen for the first time since before the pandemic, with those waiting two months or more down from 21,823 at the end of the last financial year (March 2022) to 19,248 at the end of this March (2023). This is down almost 15,000 from a peak of 34,000 in July 2022.

Community Pharmacy England (CPE) has notified pharmacy teams that starting 1 August 2024, three Hormone Replacement Therapy (HRT) medicines will be discontinued and will no longer be covered under the NHS HRT Prescription Prepayment Certificate (HRT PPC) scheme. These are Bedol® 2mg tablets, Climanor® 5mg tablets and Clinorette® tablets. Since Climanor® 5mg tablets have been discontinued, Medroxyprogesterone 5mg tablets will also be removed from the HRT PPC list, as this generic product is no longer available as a licensed HRT medicine. The CPE also noted that Provera® 5mg tablets, being an unlicensed HRT medicine, are not covered by the HRT PPC. Pharmacy staff are advised to check the NHS Business Services Authority (NHSBSA) website for the most current list of HRT medicines covered by the HRT PPC. The CPE has updated its HRT PPC medicines list to reflect these changes, which will also be updated in Part XVI of the August 2024 Drug Tariff.

Professor Michael Gordon Scott and Professor Charlotte Anne Skitterall have been recognised in the New Year Honours list 2023 for their 'service to pharmacy'. Professor Scott Director, Medicines Optimisation Innovation Centre was one among the 1,107 people to received MBE for his 'service to pharmacy' in Northern Ireland. In 1994 he established the first academic practice unit in the province in conjunction with the Queens University of Belfast. In 2004 he was made a fellow of the Pharmaceutical Society of Northern Ireland. In June 2009 he was made an honorary Professor of Pharmacy Practice at QUB. Professor Skitterall, Group Chief Pharmacist, Manchester University NHS Foundation Trust received MBE for 'services to Pharmacy'. Last year, she was appointed as a Fellow of the Royal Pharmaceutical Society. "I think it was awarded in recognition of the work I have done as chair of the National Medicines Optimisation Clinical Reference Group. I also supported the National Pharmacy Task and Finish Group for Covid Vaccine deployment," she commented. This year, dozens of NHS staff have been recognised in the New Year Honours list ahead of the health service's 75th birthday.

Health and Social Care Secretary Wes Streeting reiterated his commitment to reducing NHS waiting lists during his visit to Frimley Health NHS Foundation Trust's Heatherwood Hospital in Ascot on Friday. Streeting toured the Berkshire hospital, which is helping tackle backlogs of planned operations with dedicated surgical services, thereby cutting local waiting lists. The health secretary spoke to staff and patients at the hospital before meeting regional health representatives to discuss the issues facing services at a town hall event. His visit follows his recent call for an independent investigation into the NHS, pledging to be honest about the state of the health service and serious about fixing it. "The NHS is broken. Millions of patients are waiting too long for treatment, often in pain and discomfort," Streeting said.

Challenges in accessing the NHS waiting list are pushing more and more people toward private-funded alternatives for access, diagnosis and treatment, thereby increasing the demand for private health cover. According to a report published by health data provider LaingBuisson, the demand for private health cover, including medical and dental insurance and cash plans, has surged to its highest levels since 2008. The UK's overall health cover market reached £6.7 billion in 2022, an increase of £385 million from the previous year. During the period from 2020 to 2022, the market experienced annual growth rate of 6.1 per cent, a significant increase compared to the average annual growth rate of 1.7 per cent observed between 2008 and 2019, the research found. A total of 4.2 million people were subscribed to medical cover schemes in 2022. When dependents covered by these policies were included, the number reached 7.3 million - the highest count since 2008. LaingBuisson's analysis showed that medical cover volumes were steady through most of the 2010s, but began to increase alongside rises in the NHS waiting list from 2018.

Three leading pharmacists - professor Mahendra Patel, Asif Aziz and Ade Williams - have been recognised in Queen Elizabeth's annual New Year's honours list. Professor Patel, an academic pharmacist from West Yorkshire, was awarded an OBE for his "services to pharmacy." He told Pharmacy Business: "I am truly honoured and deeply humbled by this highly prestigious award that I have always believed was more deserving for others. "That's not to say I'm not proud of it - far from it, although for me it's not necessarily about rewards and recognition but more the intricacies of the journey I embark on and the learning and joy that those encounters bring with it. Most recently, Professor Patel - who has had a broad ranging portfolio career spanning community pharmacy, health education and health promotion, academia, and research - has been involved in promoting clinical trials across community pharmacies in the UK. His latest work has seen him act as one of the national leads for the PRINCIPLE and PANORAMIC trials, run by Oxford University - both trials seek to pioneer repurposed and new drug treatments in the community to prevent hospitalisation due to Covid-19.

Dental procedures are a necessary evil for most people. We all know that we need to go in for a cleaning and check-up at least once a year, but sometimes the cost of these procedures can be prohibitive. It's hard to know which procedures are worth the money and which ones aren't. Here is an essential list of dental procedures that are worth the money. CAVITY FILLINGS Cavities are caused by tooth decay. If left untreated, cavities can cause severe damage to your teeth. They can also lead to pain and infection. The best way to treat a cavity is to have it filled by a dentist. During the procedure, your dentist will remove the decay from your tooth and then fill the cavity with a composite material. This material is solid and durable and can help restore your tooth to its original shape and function. Modern materials and techniques have made cavity fillings much more effective than they used to be. Most fillings last for many years with proper care. ROOT CANALS It's a dental procedure that is used to treat an infected tooth. During the procedure, the dentist will remove the infected tissue from the tooth and then fill the space with a particular material. The procedures are very effective in treating infected teeth. They can also help to prevent the spread of infection to other teeth. Root canals are usually very successful, and most teeth with a root canal can last for many years. Generally, the cost of the procedure will depend on the severity of the infection and the number of teeth that need to be treated. If you are considering treatment for a root canal, it is crucial to find a qualified and experienced dentist who has experience. You want a team that assures you of world-class standards in all their procedures. This is what brings you value for your money.

The chief pharmaceutical officer (CPhO) for Wales and chief pharmacists at Boots and the Ministry of Defence are among a total of 1,134 people who received an award in the Queen's Birthday Honours list to mark her Platinum Jubilee. All three pharmacists were appointed officers of the Order of the British Empire or OBE. Andrew Evans, CPhO for Wales, was honoured "for services to the Covid-19 Response", Marc Donovan, chief pharmacist at Boots UK, "for services to pharmacy" and Sumeet Kaur Matharu, chief pharmacist at the Ministry of Defence, "for services to Armed Forces Healthcare". Giving his reaction to Pharmacy Business, Donovan said: I'm honoured to accept this recognition on behalf of the many dedicated and hard-working pharmacists and pharmacy teams that I have had the privilege to work alongside over the years.

Adding to the growing evidence of global medicine shortages, a new study has revealed that the European generic medicines market is "not in shape" to help Europe meet its public health priorities. In the past decade, the rate of generic medicines withdrawals has risen by 12 per cent, while there has been a three per cent decrease in the launch of generic products, as per Teva Pharmaceuticals' recent analysis of IQVIA data. Within the mental therapeutic area, seven per cent of generic products disappeared between 2013 and 2023, while there was a seven per cent decrease in the availability of generic cancer medicines in just six years (2017-2022). These medicines were listed on the Union List of Critical Medicines to help avoid potential shortages, as the European Commission (EC) said this could cause "significant harm to patients and pose important challenges to health systems." While mature generic products constitute the majority of the List, they remain susceptible to withdrawals, despite containing products crucial for safeguarding Europe's public health, the Teva analysis report noted. Since 2013, the number of generic products for the treatment of schizophrenia and bipolar disorder has declined by 25 per cent, with Hungary and Bulgaria experiencing the biggest loss at 83 per cent and 58 per cent respectively.

Local physician serving the Greater Los Angeles area, Dr. Michael Omidi has been featured in the 2018 top ten list of best breast surgery doctors in Beverly Hills. The annual list is published by Cosmetic Town to help consumers find the right plastic surgeon capable of delivering the most natural-looking and attractive breast augmentation results.

The NHS Business Services Authority (NHSBSA) has published the Drug Tariff Category M price list for July which reflects an increase in reimbursement level of approximately £5m per quarter. An adjustment of -£23.8m was announced, in light of the results of the margin survey (latest result up until end of December 2022), and the phasing down of the additional £100m agreed across years 4 and 5 as part of the Community Pharmacy Contractual Framework and uplifts for underlying market prices (between January - March 2023). Community Pharmacy England has agreed the adjustments based on the analysis of margin delivery and on current projections for 2023/24. It said: "The objectives are to ensure full delivery of agreed margin and smooth delivery as much as possible. As always, the impact on individual pharmacies will vary depending on dispensing mix."

The Department of Health and Social Care (DHSC) has included Tibolone 2.5mg tablets (Livial) and Prasterone 6.5mg pessaries (Intrarosa) to the list of Hormone Replacement Therapy (HRT). It has updated the June 2023 Drug Tariff (Part XVI) to include these additional HRT medicines for which patients will be able to purchase an HRT PPC. "HRT is the replacement of female sex hormones oestrogen and progesterone in women to control symptoms of the menopause. Some medicines that are converted or break down into oestrogen, progestogen or androgen hormones are prescribed for relief of menopausal symptoms. For the purposes of the HRT PPC these are included within this definition of HRT," said DHSC.

FreeStyle Libre 3 Sensors and Budesonide 500microgram orodispersible tablets sugar free have been included in the Drugs for which Discount is Not Deducted (DND) list (Part II of the Drug Tariff) from January 2024, according to Community Pharmacy England (CPE). Following applications made by CPE on behalf of pharmacy contractors, the Department of Health and Social Care (DHSC) agreed to give DND status to these products to ensure that "pharmacies are not faced with dispensing these sensors at a loss." Updated monthly by the DHSC, Part II of the Drug Tariff includes grouped and individual items. Recently launched by Abbott Diabetes Care Ltd, FreeStyle Libre 3 Sensors have also been added to the Appliances section in Part IXA of the January 2024 Drug Tariff. As the sensors can only be ordered by pharmacies directly from the manufacturer without any discount, CPE requested the DHSC to exempt this appliance from any discount deduction.

As the Easter holiday draws near, pharmacies across Hampshire and the Isle of Wight are readying themselves to provide essential healthcare services to residents. Operational throughout Good Friday (March 29), Easter Sunday (March 31), and Easter Monday (April 1), these pharmacies stand poised to offer vital support to those in need. NHS England has raised awareness by releasing a comprehensive list of pharmacies scheduled to operate during the holiday period. Hampshire residents, including those in Southampton and Portsmouth, can access detailed information about open pharmacies on the NHS England website, along with separate listings for the Isle of Wight. However, it's important to note that opening times may vary, prompting individuals to confirm details before visiting, as schedules are subject to change. Beyond merely dispensing prescriptions, pharmacies are equipped to provide expert advice on minor illnesses and administer treatments for common conditions. This includes addressing issues such as shingles, sore throats, infected insect bites, earaches, sinusitis, impetigo, and uncomplicated urinary tract infections (UTI) under the Pharmacy First scheme.

The new Labour government has pledged to deliver an extra 40,000 NHS appointments, operations and diagnostics every week, equivalent to two million a year, to tackle the ongoing waiting list crisis. It aims to ensure that 92 per cent of patients start routine hospital treatment within 18 weeks by the end of this parliament - a target that has not been met for nearly a decade. However, a new analysis by healthcare consultancy CF (Carnall Farrar) and the NHS Confederation has revealed that these extra appointments alone will not be enough to achieve the 18-week Referral To Treatment (RTT) target by 2028/29. The study estimates that 40,000 extra appointments per week would deliver only about 15 per cent of the additional activity required to hit the 18-week target, assuming demand continues to grow at current rates and care delivery remains unchanged. While the report acknowledged that increasing capacity is a positive step, it stresses that further reforms and transformations in care pathways are necessary to bridge the gap.

Health and Social Care Secretary Wes Streeting has on Wednesday laid out his vision for reforming the National Health Service, stating that the NHS is "broken but not beaten" after years of Conservative governance. In his address to the annual Labour Party conference in Liverpool, Streeting highlighted the current challenges facing the NHS, including record-high waiting lists, ambulance delays, and difficulties in accessing GP appointments. Stressing that "reform or die" is the choice facing the NHS, he rejected the idea of simply increasing funding without systemic changes. Streeting noted some initial successes since Labour took office, including employing 1,000 more GPs and negotiating an end to junior doctors' strikes. He revealed that crack teams of top clinicians will be deployed to hospitals across the country to roll out reforms: to treat more patients and cut waiting lists.